Report Library
All ReportsNon-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast
March 23, 2020
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase
pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also
discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and
selpercatinib.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Non-Small Cell Lung Cancer (NSCLC) |
Additional Resources:
- Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK
- 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
- 2019 Post-ESMO Podcast
- Deconstructing the KRAS+ market opportunity
- 2019 Post-ASCO Podcast
- 2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
- Informa Pharma Intelligence Podcast: Pre-ASCO Edition
- 2019 Pre-ASCO Report